Nonapprovable letter to Allergan

Share this article:
The FDA has issued a nonapprovable letter to Allergan for tazarotene capsules (oral tazarotene) for the treatment of psoriasis.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.